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ABSTRACT 
Vitiligo is an epidermal disorder causes depigmented patches resulted from the loss of 
melanocytes, Autoimmunity hypotheses strongly supports that the immune system compartments 
responsible in the development of vitiligo. Adenosine MonoPhosphate kinase (AMPK) signaling 
plays a role in regimentation in vitiligo. In this present study, set of ligands selected to dock 
against AMPK protein in the AMP binding site using FlexX software. Based on the scores and 
protein-ligand interactions selected ligands were analyzed for its binding affinity and protein 
ligand stability for its further drug development process.  
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1. INTRODUCTION  
 Vitiligo is a rare and chronic autoimmune disease in which the body attacks its own 
melanocytes in the epidermis, causing depigmentation in irregular patches of skin and hair. 
Vitiligo affects 0.5-2% of the world population [Ray etal., 1994]. Currently there is no cure for 
Vitiligo. These with the disease often use topical creams and concealers to diminish the 
appearance of depigmented patches. Those with severe cases have sometimes resorted to 
skingrafts and photo therapies. Corticosteroids have been used in the treatment of vitiligo since 
1970[ Doghim etal.,2011].  
 ransrepression of NF-kB leads to suppression of immune system. Physical interaction 
between GR and p-65 subunit of NF-kB leads to inactivation of NF-kB. Because N-terminal of p-
65 subunit has the strong capacity for transactivating potential of NF-kB. Interaction between N-
terminal subunit p-65 and two critical aminoacids in the C-terminal zinc finger leads to the 
inactivation of NF-kB results to down regulate the immune system [Liberman et al.,2007].  
 AdenosineMonophosphateprotien kinase (AMPK) signaling mediates many cellular 
processes. From all AMPK signaling activation leads to Nf-kB deactivation, it helps in 
autoimmunity suppression in vitiligo patients. As well as imbalance of glucose uptakes found in 
vitiligo patients, high glucose levels inactivate AMPK so using AMPK activators helps to 
improve glucose metabolism it helps in repigmentation (Viollet.B et al.,2009, 2011).  
 In this present study set of 6 ligands which are as follows Ascorbic acid, Berberine, 
Chrysin, Kaempferol, Pinocembrine, Piperine allowed to binding in the AMP binding site and 
also AMP allowed to binding in the AMP binding site then compare the results (scores) of all the 
6 compounds with AMP result (score). There were no docking studies carried out to study the 
protein-ligand stability based on the scores for AMPKinase with these set of ligands. 
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MATERIALS AND METHODS   
Protein Preparation 
 
 
 
 
 
 
 
 
 
 
Fig1: Protein AMPK (2Y94) 
 Protein structure was downloaded from web based server www.rcsb.org. Selected protein 
structure was prepared using following steps using FlexX software. 
 Chain selection, Cofactor selection, if the structure is ligand bound in the next step the 
reference ligand must be selected to set active site pocket where the input ligands allowed binding 
into it properly. In non-ligand bounded structures active site pockets are predicting by specifying 
active site surrounding residues in this step. In this step we have to specify the residues included 
for docking analysis. Also if the protein contains water molecules we have to eliminate from the 
protein. Then the preprocessing of receptor done for further docking calculations. 
 
Ligands Preparation 
 Ligands are imported in SDformat files then the docking process will be carried out in 
FlexX software. 
 
Docking calculations 
 Based on the mentioned algorithm, FlexX docking program performed for the set of 
ligands docked against set of protein structures.  
 
Table1 Interaction energies and molecular hydrogen bond interactions of selected ligands against AMPK 
protein. 
S.No Ligand name 
Ligand atom: 
AMPK 
Interacting 
Residues 
H-bond Length 
(Å) 
FlexX 
scores 
1 
 
Berberine 
O2…HH21 
O2…HZ2 
O3…HH12 
HH…O1 
HH21…O1 
ARG69 
LYS169 
ARG268 
ARG298 
ARG298 
1.69 
2.09 
2.01 
1.97 
1.82 
-24.4 
2 
 
Piperine 
O2…HH21 
O2…HZ2 
O1…HH12 
O3…H 
O3…HH11 
ARG69 
LYS169 
ARG268 
HIS297 
ARG298 
1.95 
1.91 
2.08 
1.82 
1.70 
-25.1961 
 
3 
 
Pinocembrine 
H31…O 
O1…HG 
O4…HH11 
O4…HH21 
O2…H 
O2…HH11 
ILE239 
SER241 
ARG268 
ARG268 
HIS297 
ARG298 
1.93 
2.03 
2.01 
2.09 
1.60 
1.94 
-20.693 
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4 
 
Chrysin 
H29…OD2 
O4…HH11 
O3…H 
O3…HH11 
ASP244 
ARG268 
HIS297 
ARG298 
1.67 
1.68 
1.65 
2.07 
-21.7023 
 
5 
Ascorbic acid 
 
O5…HZ2 
H17…OD2 
H19…OD2 
H19…OD2 
H…O6 
HH…O6 
 
LYS169 
ASP244 
ASP244 
ASP244 
HIS297 
ARG298 
1.84 
2.23 
2.23 
1.91 
2.01 
1.53 
-17.2892 
 
(A)  Pinocembrine                                                           (B) Berberine 
                 
               
(C) Piperine                                                                       (D)Chrysin 
 
           
               
Figure 3 (i) Docked confirmation of AMPK with top ranked docked poses of selected ligands showing 
Interactions with non-ligand residues involved in the hydrogen (Black colour) & 
Hydrophobic interactions (Green color). 
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The results are in the form of spread sheets it consists of FlexX score, Total score- total docking 
score, RMS score, etc. 
 
 AMPK activation with the above said ligands (Ascorbic acid, Berberine, Chrysin, 
Pinocembrine, Piperine) studied computationally since it is traditionally using in a blind manner 
to cure this disorder. FlexX, CLC drug software employed to study the ligand binding affinity as 
well as protein-ligand stability. AMP binding site residues in the crystal structure of AMPK 
protein were compared with the docking results binding site residues of the selected ligands in the 
AMPK protein. It helps us to ensure the preliminary insilco analysis proved the activation 
efficacy. According to FlexX scores the ligand efficacy descended as follows (Table1) Piperine> 
Berberine> Chrysin > Pinocembrine > Ascorbic acid. 
 
Analysis of hydrogen bond  
 Based on the results from FlexX, when analyzing hydrogen bond forming amino acids 
here AMP binding site residues are compared with the resulting interacting residues. LYS169A, 
SER241A, ASP244A, ARG268A, ARG298A, HIS297A these are the amino acid residues similar 
to AMP interacting amino acid residues (Figure 3). So the testing ligand components may also 
have the property to activate AMPK protein like AMP molecule. Some additional interacting 
residues ARG69A, ILE239A were found in the binding site. All the interacting residues are nearer 
to the ligand which shows the protein-ligand stability.  
 
Analysis of Hydrophobic interactions  
 ILE239, SER241, PHE243, ASP244, HIS267, ARG268, VAL296, HIS297, ARG298, are 
the hydrophobic amino acid residues found in top scoring docked poses of ligands (Berberine and 
Piperine) against AMPK protein 
 From the results, Piperine, and Berberine could be the lead components based on the 
binding affinity (Docking scores) and protein-ligand stability (Molecular interactions). For 
AMPKII protein. 
 
(E) Ascorbic acid 
                      
Figure 3 (ii): Docked confirmation of AMPK with top ranked docked poses ofselected ligands showing  
Interactions with non-ligand residuesinvolved in the hydrogen (Black colour) &   Hydrophobicinteractions 
(Green color). 
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